Fujian Haixi Pharma submits China IND for HX9428 Phase IIa trial in diabetic macular edema

• Fujian Haixi Pharmaceuticals submitted a China IND to start a Phase IIa trial of oral eye drug HX9428 in diabetic macular edema.
• Filing was made to the NMPA’s Center for Drug Evaluation on Aug. 31, 2026, adding a second indication to the program.
• HX9428 previously received FDA Fast Track designation; Phase II trials in wet age-related macular degeneration are ongoing in China and the US.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fujian Haixi Pharmaceuticals Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260902-12316772), on September 02, 2026, and is solely responsible for the information contained therein.